As per our report, the size of the global clinical microbiology market was worth USD 6.05 billion in 2024 and is projected to grow to USD 10.58 billion by 2029. The market is estimated to register a CAGR of 11.80% during the forecast period.
Microbiology testing, also known as Clinical microbiology, is a discipline that encompasses a broad range of testing methodologies for a diverse group of microorganisms. Clinical microbiology laboratories perform aerobic and anaerobic tests related to bacteriology, parasitology, mycobacteriology, and virology. According to the World Health Organization (WHO), HIV, malaria, tuberculosis (TB), and diseases like hepatitis and leishmaniosis together accounted for 4.3 million deaths worldwide. About 7 million people are affected by influenza in the U.S. itself; thus, there is a high demand for clinical microbiology as it helps to detect the infection much earlier.
There is an increasing awareness about the early detection of infection to avoid risk. It is boosting the microbiology testing market growth. The government and non-government organizations promote new technology in clinical microbiology as infectious diseases are increasing globally. Clinical microbiology uses many rapid tests to detect specific microbial antigens or nucleic acids in primary non-tissue specimens, which help identify the infection much quicker in serious conditions. It is propelling the market growth. There is an excellent advancement in the technology of clinical microbiology as it requires an accurate and reliable method to identify clinically significant microorganisms that are propelling the market growth. Over the last several years, many microbial laboratories have implemented automation to process isolation and detect a specific microorganism.
Clinical microbiology requires well well-trained and skilled workforce as they need to handle pathogenic microorganisms. The equipment used in this test is high-cost and difficult to handle, which is estimated to hamper the growth of the global microbiology testing or clinical microbiology market. The rise in technical issues in real-time is also hindering the demand of the market. Strict rules by the government in approving new products are further expected to impede the market's growth.
The world has been placed on high alert due to the novel coronavirus (COVID-19) pandemic. The WHO declared a pandemic in the world in early March 2020. This pandemic has had a major impact on the clinical microbiology industry at an early stage. The industry is confronted with problems in the manufacturing and supply chain, such as the timely delivery of goods to end-users. Due to a shortage of qualified lab technicians to conduct diagnostic tests, limited support for research and development, and lockdowns, the supply of clinical microbiology products to end-users has been reduced. This pandemic forced the temporary closing of many research institutes across the world; due to this, the market was severely impacted during the early stages of the COVID-19 pandemic. Clinical microbiology is the study of microorganisms that cause infection in humans. According to the Centers for Disease Control and Prevention, the number of visits to physician offices with infectious and parasitic diseases as the primary diagnosis was 16 million in 2018. As a result of the outbreak of COVID-19, the demand for microbiology testing/clinical microbiology market has a positive growth rate.
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2023 to 2029 |
|
Base Year |
2023 |
|
Forecast Period |
2024 to 2029 |
|
Segments Covered |
By Product, Application, Disease Area, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC, PESTLE Analysis, Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leader Profiled |
Danaher Corporation (U.S.), Becton, Dickinson, and Company (U.S.), Cepheid (U.S.) Abbott Laboratories Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), Alere Inc. (U.S.), Bruker Corporation (U.S.), and Hologic, Inc. (U.S. |
The instruments segment is expected to hold the largest share of the microbiology testing market over the forecast period. Factors such as the essential acquisition of conventional laboratory instruments amid end-users, advanced technologies in the area of molecular techniques & proteomics, and also the continuing trend of laboratory between clinical laboratories are boosting the market growth of the market.
The clinical segment held the highest share of the microbiology testing market over the analysis period. A growing number of microbiology-based clinical trials and clinical services worldwide greatly influence the market's demand.
The respiratory diseases segment accounts for the highest share of the microbiology testing market. Factors like the increasing patient population suffering from respiratory diseases and the growing number of COVID-19 cases are surging the market's growth rate.
As of 2023, North America leads the market, accounting for a significant stake in the global market share. North America’s lead is warranted by the presence of key market players in the region, a relatively high number of registered treatments, and the increasing use of cartilage repair or regeneration to treat sports injuries and other accidents. Europe comes in second in terms of market share due to rising awareness about blood-related disorders and the swift availability of treatment in plasma fractionation.
However, Asia-Pacific is expected to outpace all other regions by clocking the highest CAGR during the forecast period, majorly because of the rising number of hospitals and clinical diagnostic laboratories in India and China; expanding research capabilities for the development of innovative and affordable clinical microbiology testing procedures across India, China, and Japan; and rising incidences of infectious diseases.
The major players in the global microbiology testing market profiled in the report are Danaher Corporation (U.S.), Becton, Dickinson, and Company (U.S.), Cepheid (U.S.) Abbott Laboratories Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), Alere Inc. (U.S.), Bruker Corporation (U.S.), and Hologic, Inc. (U.S.), among others. The Global Microbiology Testing Market is quite consolidated, with the key companies spending a lot of money and time on R&D to expand market boundaries while also focusing on product differentiation. For Instance, In June 2020, Hoowaki LLC developed a one-piece injection-molded design for the COVID–19 swabs.
By Product
By Application
By Disease Area
By Region
Frequently Asked Questions
Challenges include the need for skilled personnel, the time-consuming nature of traditional testing methods, and the constant evolution of microbial strains, which may require continuous updates to testing protocols.
Microbiology testing helps identify and control the spread of infectious diseases, ensures the safety of food and water supplies, and supports the development and quality assurance of pharmaceuticals, ultimately contributing to public health and safety.
Regulations for microbiology testing vary by region and application. Organizations such as the FDA (Food and Drug Administration) in the United States and the European Medicines Agency (EMA) in Europe set standards and regulations for microbiology testing in their respective domains.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region